Background: The long-term safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; FlutiformÔ) was assessed.
Introduction
A sthma is a Chronic Disorder of the airways. [1] [2] [3] Inhaled corticosteroids (ICSs) are the mainstay of persistent asthma therapy for targeting airway inflammation and hyperresponsiveness. Long-acting b 2 -agonists (LABAs) allow bronchodilation to be achieved for at least 12 hr 2, [4] [5] [6] and are used together with ICSs as part of a stepwise treatment approach, when asthma is suboptimally controlled on ICSs alone. 2 For patients with persistent asthma, ICS/LABA combination therapy has been shown to be clinically efficacious, more so than either doubling the dose of ICS or administration of ICSs in combination with other therapeutic agents. 4, [7] [8] [9] [10] [11] In addition, in vitro research suggests that, at the molecular level, there is a synergy between the therapeutic effects of ICSs and LABAs when administered together. 6, [12] [13] [14] Moreover, in vivo research on airway cells from patients with mild asthma suggests that the combination of an ICS and a LABA shows enhanced effects compared with either drug alone. 15 Despite significant advances in asthma management, [16] [17] [18] [19] [20] [21] poor control of symptoms and exacerbations persist for a substantial proportion of patients. This may be a consequence of inadequate drug delivery due to poor inhaler technique, the choice of asthma therapy, or other factors such as lack of patient adherence to prescribed treatment. 1, [22] [23] [24] [25] [26] [27] The capacity for therapies to reach the small airways, which are an important site of inflammation in asthma, may also affect treatment efficacy. 28, 29 However, the clinical significance of ICS/LABA deposition in the distal airways has not yet been demonstrated. 30, 31 The ICS, fluticasone propionate (fluticasone), delivers a potent and sustained anti-inflammatory effect. 17, [32] [33] [34] The LABA, formoterol fumarate (formoterol), has a fast onset of action and a prolonged bronchodilatory effect.
Fluticasone and formoterol have now been combined in a single aerosol inhaler (fluticasone/formoterol; FlutiformÔ). This study assessed the long-term safety and efficacy of this new combination aerosol in adolescents and adults with mild to moderate-severe asthma.'
Materials and Methods

Study design
This was a long-term (up to 12 months), open-label study assessing the safety and efficacy of fluticasone/formoterol 100/10 lg and 250/10 lg, administered twice daily (b.i.d.). The study was conducted in five European countries (Germany, Hungary, Poland, Romania, United Kingdom; EudraCT number: 2005-003518-14; US NCT number: NCT00394121), in accordance with ICH Good Clinical Practice (GCP), the Declaration of Helsinki, the European Union Clinical Trials Directive (2001/20/EC), the GCP Directive (2005/28/EC), and the prevailing local laws and customs of the participating countries. Independent Ethics Committees at each center reviewed and approved the protocol, and written informed consent was obtained from all patients, or the parents or legal guardians of those patients below 18 years of age, prior to screening.
Patients
Adults and adolescents ( ‡ 12 years) with mild to moderate-severe asthma were eligible for enrollment if they had a history of asthma for ‡ 12 months 39 and a documented use of ICS asthma maintenance therapy for ‡ 4 weeks prior to screening at a dose not greater than 500 lg/day inhaled fluticasone or equivalent ICS. Eligible patients had to demonstrate a forced expiratory volume in the first second (FEV 1 ) of between 40% and 85% (inclusive) of predicted normal values at both screening and baseline (week 0), following appropriate withholding of asthma medication. At screening, patients were required to discontinue any LABA treatment at least 24 hr before the visit for pulmonary function testing and not use a short-acting bronchodilator as a rescue medication within 6 hr prior to the visit. At baseline, patients were not permitted to take fluticasone or rescue medication (salbutamol) within 12 hr or 6 hr, respectively, before the visit. In addition, patients had to show a documented reversibility of ‡ 15% in FEV 1 within 6 months of screening. During the 14 -3 day run-in period, patients were administered fluticasone by hydrofluoroalkane (HFA) pressurized metered-dose inhaler (pMDI) b.i.d. and had to use ‡ 2 inhalations/day of rescue salbutamol for ‡ 3 days, as well as experience ‡ 1 night with sleep disturbance or ‡ 3 days with asthma symptoms. AU2 c Exclusion criteria included life-threatening asthma within 12 months, systemic (oral or injectable) corticosteroid medication within 3 months, omalizumab within 6 months, or leukotriene receptor antagonist within a week prior to screening. Patients with an upper or lower respiratory tract infection within 4 weeks prior to screening or during the runin, significant, nonreversible pulmonary disease, a smoking history (equivalent to 10 pack years, or had smoked within 12 months), or receiving b-blocking agents, tricyclic antidepressants, monoamine oxidase inhibitors, astemizole, quinidine-type antiarrhythmics, or potent CYP3A4 inhibitors in the week prior to the screening visit were also excluded.
During the treatment period, fluticasone/formoterol was administered for either 6 months or 12 months. The treatment period comprised scheduled visits at weeks 2 and 4, and monthly thereafter. Patients were given a diary card and a peak flow meter and, during the run-in, entered information into an Interactive Voice Response System diary. During both the run-in and treatment periods, patients recorded their predose peak expiratory flow rate (PEFR) twice daily, their daily assessment of asthma symptoms, and daily rescue medication use.
Interventions
During the 14 -3 day run-in period, patients were assigned to one of two groups ( b F1 , depending on whether they had 100 lg/day or 250 lg/day ICS during the run-in period. Study medications were administered via a pMDI without the use of a spacer, and patients were instructed to take morning and evening doses timed apart as evenly as possible. Patients were also required to leave a 1-min interval between inhalations and wash their mouth thoroughly after dosing. Rescue salbutamol (100 lg/actuation) was available, as needed, throughout both the run-in and treatment periods.
Safety assessments
Safety assessments included medical history at screening, physical examinations at screening and baseline, and vital sign assessments prior to pulmonary function tests (PFTs) Patients were withdrawn if they experienced severe asthma exacerbations requiring medical intervention. A mildto-moderate asthma exacerbation was defined as night awakenings due to asthma on 2 or more consecutive days, or the additional use of rescue medication of ‡ 3 inhalations/ day with respect to baseline on 2 or more consecutive days, or morning predose PEFR > 30% below baseline values on at least 2 consecutive days. The baseline values for the run-in period were defined as the PEFR measured at screening; for the treatment period, this was defined as the average of three morning PEFR measurements taken at baseline. A severe asthma exacerbation was defined as the deterioration in asthma symptoms requiring additional therapy, e.g., a systemic steroid, a visit to the emergency room, or hospitalization due to asthma.
Patients were also withdrawn if their prebronchodilatory FEV 1 decreased to < 40% of predicted normal values, prebronchodilator PEFR decreased to £ 75% of baseline average values on 4 consecutive days, if they used ‡ 12 actuations/ day of rescue salbutamol on ‡ 3 days/week, recorded a sleep disturbance score of ‡ 3 on three consecutive nights, used prohibited medications for asthma exacerbations, or experienced a serious or unexpected AE. Patients who withdrew from the study due to an AE were followed up with appropriate clinical and/or laboratory tests until satisfactory resolution of the AE.
Patients returned all used and unused study drug to the site at each visit. During the run-in and treatment periods, patients recorded the number of inhalations of fluticasone and the time and number of inhalations of study drug, respectively. At each study visit, the dose counters on the fluticasone/formoterol inhalers were checked to confirm the number of actuations taken. Patients with < 70% adherence to study medication were withdrawn from the study.
Efficacy assessments
Efficacy assessments were the secondary endpoints of this study and included the spirometry performed at screening, within 30 min before morning dosing, and 1 hr after dosing at each visit during the treatment period. LABA medication
FIG. 2. Patient flow diagram.
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was discontinued at least 24 hr and short-acting b-agonist medication within 6 hr prior to the first spirometry at screening, and the use of rescue salbutamol within 6 hr of all scheduled PFTs. All PFTs were carried out using a spirometer 40 and included the forced vital capacity (FVC) (the maximum volume of air expired as forcefully and as rapidly as possible after maximum inspiration), PEFR (the maximum flow rate obtained during the FVC procedure), FEV 1 , and FEV 1 % predicted based on the patient's age, height, and gender, determined according to guidelines for adults ( ‡ 17 years) 41 and for adolescents (12-16 years). 42 During the study, patients recorded their daily morning and evening predose PEFR, the time and number of inhalations of both study and rescue medication (patients were to contact the study site if they had taken 12 or more inhalations of rescue medication on any one day), asthma symptom scores [from 0 (no symptoms) to 5 (asthma was so severe that the patient was unable to go to work or school or carry out normal daily activities)], and sleep disturbance scores [from 0 (patient slept through the night and experienced no asthma) to 4 (patient could not sleep at all because of asthma)].
Statistical analyses
No statistical analyses were performed on the safety parameters.
Statistical analyses for FEV 1 , FVC, and PEFR and the changes from baseline to each subsequent visit and within each dose group were analyzed using a paired t test. All statistical analyses were performed at the 0.05 significance level unless otherwise noted.
The safety population comprised all enrolled patients who had at least one inhalation of study medication; the full analysis set (FAS) included patients in the safety population with at least one efficacy measurement at baseline and post baseline, and the per-protocol (PP) population comprised patients in the FAS without a major protocol violation. Sample size estimates were not formally calculated but were 
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based on the ICH guidelines on the minimum number of patients required for the long-term treatment of noncritical conditions.
Results
Overall, 472 patients entered the treatment period and 413 completed the study ( F2 c In general, the two treatment groups were well matched with respect to baseline characteristics ( T1 c Table 1 ). The 250/ 10 lg b.i.d. treatment arm had a ‡ 5% higher incidence of patients with a medical history that included abnormalities in the cardiovascular and genitourinary systems, and the 100/10 lg b.i.d. group had a higher proportion of patients in the 12-17-year age group compared with the 250/10 lg b.i.d. group (17.9% vs. 6.5%).
Safety and tolerability
The duration of exposure to study medication is presented in T2 c Table 2 . Overall, 174 (36.9%) patients reported AEs ( T3 c Table 3 ). The majority were mild to moderate in severity; those occurring with an incidence of > 1% are presented in T4 c Table 4 . The numbers of patients reporting severe AEs are displayed in T5 c Table 5 ; asthma was the only severe AE reported by more than one patient. In total, 18 (3.8%) patients reported AEs possibly or probably related to study medication, including asthma (n = 2) and dysphonia (n = 5) reported for more than one patient.
No deaths were reported. Five patients in each treatment group experienced a total of 12 serious AEs, all deemed either not or unlikely to be study medication-related. Three patients (1.3%) receiving 100/10 lg b.i.d. and 11 (4.4%) receiving 250/10 lg b.i.d. fluticasone/formoterol discontinued from the study, at least in part, due to an AE; two patients who received 100/10 lg b.i.d. had an asthma exacerbation and anxiety-induced respiratory syndrome, respectively; six patients who received 250/10 lg b.i.d. experienced severe dyspnea during activity, worsening of asthma, a serious asthma exacerbation, increased breathlessness, increased asthma symptoms, and upper respiratory tract infection, respectively.
Six patients had laboratory abnormalities that were mild to moderate, nonserious AEs: one patient each had increased white blood cell and neutrophil counts, increased white blood cell count, increased platelet count, increased aspartate aminotransferase (AST) and alanine aminotransferase, increased AST, and increased sodium. Four patients had elevated glucose values that met the criteria for potential clinical significance, three of whom had a history of diabetes, and all had high plasma glucose levels at each visit, including at screening and at baseline.
Three patients reported AEs related to increased blood pressure: two in the 250/10 lg b.i.d. group reported worsening hypertension (not study medication-related), and one in the 100/10 lg b.i.d. group reported arterial hypertension (possibly study medication-related). All AEs were assessed as mild to moderate in severity and resolved or stabilized with medication.
Four patients had one postbaseline ECG QTcF interval that was > 500 msec, but continued on the study medication with no subsequent QTcF intervals of > 500 msec and without cardiovascular or dysrhythmia events associated with the QT prolongation. Overall, clinical laboratory tests, vital sign evaluations, and ECGs showed no abnormal trends or dose-response-related changes. 
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Asthma exacerbations
In total, 53 (11.2%) patients reported asthma exacerbations, including 46 (9.7%) reporting mild to moderate exacerbations [22 (9.8%) 
Efficacy
Efficacy analyses were carried out on the FAS and showed statistically significant improvements overall and for both treatment groups for each efficacy assessment (
ST1ÀST4 c
Supplementary Tables S1-S4; Supplementary Data are available online at www.liebertonline.com/jamp). The data shown in F3 c Figure 3 illustrate the time b AU3 course of pooled efficacy results for all patients that reached month 12. Data show that, within the first 2 months of treatment, overall efficacy parameters improved and that good results were sustained throughout the 12-month treatment period.
Discussion
Fluticasone/formoterol combination therapy demonstrated a good safety and tolerability profile over the 12-month study period. Altogether, 174 patients (36.9%) reported AEs, including 67 (29.9%) in the 100/10 lg b.i.d. and 107 (43.1%) in the 250/10 lg b.i.d. group, with the majority either mild or moderate in severity. The incidence of AEs observed with fluticasone/formoterol in the present study is in line with that observed in previous long-term studies of ICS/LABA combinations. 43, 44 For example, the overall incidence of AEs was 48.6% with fluticasone propionate/ 43 Thus, the rates of AEs reported here do not appear to be unusual for combination therapy administered over a period of up to 1 year.
The AE profile observed with the fluticasone/formoterol combination is consistent with that of the individual component drugs and in line with those reported for other ICS/ LABA combinations. The most common AEs observed with fluticasone/salmeterol therapy in a 1-year study were nasopharyngitis (13%), upper respiratory tract infection (13%), and headache, sinusitis, and influenza (each 5%) 19, 45 ; the type and incidence of AEs were similar to those for fluticasone alone. The most common treatment-related AEs reported in previous studies included headache (incidence 1-5%), throat irritation/cough (1-5%), hoarseness/dysphonia (2-7%), and oropharyngeal candidiasis (1-5%). 46 With the budesonide/formoterol combination, the most common AEs observed in a 6-month study were respiratory infection (36%), viral infection (10%), bronchitis, pharyngitis, and headache (each 6%), and sinusitis, rhinitis, and dysphonia (each 5%). 47 Common treatment-related events reported with beclometasone/formoterol in a 24-week study include 
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headache, hoarseness, and pharyngitis. 48 Moreover, comparison studies suggest no significant differences in AE profile between the different ICS/LABA combinations 43, 44, 49, 50 or between ICS/LABA combinations and ICS therapy alone. 51, 52 In the current study, nasal or oropharyngeal AEs made up a notable proportion of the AEs. This finding is not unexpected given the known oropharyngeal effects of ICS therapy. 53, 54 In the study, the majority ( > 75%) of these events were mild in severity, none of the events were severe, and most were not considered related to study medication.
Patients administered fluticasone/formoterol 100/10 lg b.i.d. reported fewer AEs related to the respiratory system compared with those administered 250/10 lg b.i.d., which may be reflecting differences in the underlying asthma severity between the two groups. The patients assigned to this treatment group were already receiving 250-500 lg/day fluticasone (or equivalent) prior to study enrollment compared with those in the 100/10 lg b.i.d. group who were administered 100-249 lg/day fluticasone (or equivalent). The greater incidence of dysphonia (2.4% vs. 0.4%), for example, may have been a consequence of the increased exposure of patients to higher doses of ICS in the 250/10 lg b.i.d. group compared with the 100/10 lg b.i.d. treatment arm 55 and may also have been affected by the fact that spacers were not used in this study. The laryngeal deposition of the ICS has been reported to cause the myopathy of the arytenoid muscles and dysphonia, which seems to be doserelated. 55 No deaths were reported, and the 12 serious AEs experienced by the 10 (2.12%) patients were considered not related (n = 9) or unlikely related (n = 3) to study medication, including three that were respiratory system-related (pneumonia, anxiety-induced respiratory syndrome, and asthma exacerbation).
Asthma exacerbations, principally mild to moderate, were reported by 53 (11.2%) patients; only 9 (1.9%) experienced severe exacerbations, with the incidence of severe exacerbations *1% higher in the 250/10 lg b.i.d. than in the 100/ 10 lg b.i.d. group (2.4% vs. 1.3%, respectively). It could be concluded that this is possibly a result of the severity of the underlying disease in the group receiving the higher dose of combination therapy.
The clinical assessments and vital signs showed no significant or abnormal trends or dose-response changes in either treatment group over the 6-12-month period.
The secondary endpoints successfully demonstrated the efficacy of the combination therapy at both dose strengths. Clinically important improvements were seen at the a = 0.001 level for mean changes in the predose as well as in the predose to 1-hr postdose assessments of FEV 1 , FEV 1 % predicted, PEFR, and FVC measurements: improvements were observed within a short time period, at each assessment time point, throughout the treatment period, and for both treatment arms and overall.
As with all chronic diseases, patient adherence to study medication is an important factor. [55] [56] [57] [58] Patients in this study demonstrated good adherence to therapy in both dosage groups, with only 23 (4.9%) considered protocol violators because of noncompliance: this is especially noteworthy considering the study period (up to 12 months). The fact that patients underwent monthly visits in a clinical trial setting may have had a positive effect on adherence to study treatment. However, the rapid bronchodilation reported with fluticasone/formoterol therapy, reflecting the rapid effect of the formoterol component of the combination, 59 could also be an important factor in improving treatment adherence. This notion is supported by the fact that nonadherent patients would improve their adherence if they were able to feel a therapy working soon after taking it. 60, 61 The safety and efficacy of both fluticasone and formoterol are extensively documented in the literature. 5, 17, [32] [33] [34] [35] [36] [37] [38] The administration of fluticasone/formoterol from a single pMDI allows patients to experience rapid bronchodilation after dosing while providing sustained anti-inflammatory effects, via a commonly used and familiar device. 26 Together, these factors may provide incentives for patients to adhere to their treatment regimen and achieve better asthma control.
In conclusion, this study successfully demonstrated the long-term safety and efficacy of the new fluticasone/ formoterol combination therapy for patients whose asthma is not adequately controlled with ICS monotherapy or is already controlled with an ICS/LABA combination.
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